Cargando…

Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARγ stimulation

BACKGROUND: Type 2 diabetes mellitus (T2DM) is commonly associated with both microvascular and macrovascular complications and a strong correlation exists between glycaemic control and the incidence and progression of vascular complications. Pioglitazone, a Peroxisome proliferator-activated receptor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Biscetti, Federico, Straface, Giuseppe, Arena, Vincenzo, Stigliano, Egidio, Pecorini, Giovanni, Rizzo, Paola, De Angelis, Giulia, Iuliano, Luigi, Ghirlanda, Giovanni, Flex, Andrea
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745363/ https://www.ncbi.nlm.nih.gov/pubmed/19737384 http://dx.doi.org/10.1186/1475-2840-8-49

Ejemplares similares

High-Mobility Group Box-1 Protein Promotes Angiogenesis After Peripheral Ischemia in Diabetic Mice Through a VEGF-Dependent Mechanism
por: Biscetti, Federico, et al.
Publicado: (2010)

Increased FGF23 serum level is associated with unstable carotid plaque in type 2 diabetic subjects with internal carotid stenosis
por: Biscetti, Federico, et al.
Publicado: (2015)

High Mobility Group Box-1 and Diabetes Mellitus Complications: State of the Art and Future Perspectives
por: Biscetti, Federico, et al.
Publicado: (2019)

Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects
por: Giovannini, Silvia, et al.
Publicado: (2017)

Correction to: Association between carotid plaque vulnerability and high mobility group box‑1 serum levels in a diabetic population
por: Biscetti, Federico, et al.
Publicado: (2021)

Association between carotid plaque vulnerability and high mobility group box-1 serum levels in a diabetic population
por: Biscetti, Federico, et al.
Publicado: (2021)

Dietary Risk Factors and Eating Behaviors in Peripheral Arterial Disease (PAD)
por: Cecchini, Andrea Leonardo, et al.
Publicado: (2022)

The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
por: Swanson, Christine R, et al.
Publicado: (2011)

Vascular endothelial growth factor (VEGF) fails to improve blood flow and to promote collateralization in a diabetic mouse ischemic hindlimb model
por: Roguin, Ariel, et al.
Publicado: (2003)

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity
por: Jacques, Vincent, et al.
Publicado: (2021)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy
por: Balestra, Elia, et al.
Publicado: (2023)

Effects of Pioglitazone Mediated Activation of PPAR-γ on CIDEC and Obesity Related Changes in Mice
por: Shamsi, Bilal Haider, et al.
Publicado: (2014)

Diet Modifies Pioglitazone's Influence on Hepatic PPARγ-Regulated Mitochondrial Gene Expression
por: Kulkarni, Sakil, et al.
Publicado: (2020)

Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs
por: Lee, Min A, et al.
Publicado: (2017)

Carvacrol and PPARγ agonist, pioglitazone, affects inhaled paraquat-induced lung injury in rats
por: Amin, Fatemeh, et al.
Publicado: (2021)

Alteration of PPAR‐GAMMA (PPARG; PPARγ) and PTEN gene expression in acute myeloid leukemia patients and the promising anticancer effects of PPARγ stimulation using pioglitazone on AML cells
por: Esmaeili, Shadi, et al.
Publicado: (2021)

Enhanced Collateral Growth by Double Transplantation of Gene-Nucleofected Fibroblasts in Ischemic Hindlimb of Rats
por: Zhang, Ziyang, et al.
Publicado: (2011)

Requirement of β1 integrin for endothelium-dependent vasodilation and collateral formation in hindlimb ischemia
por: Henning, Carina, et al.
Publicado: (2019)

Effects of PPARγ Agonist Pioglitazone on Redox-Sensitive Cellular Signaling in Young Spontaneously Hypertensive Rats
por: Dovinová, Ima, et al.
Publicado: (2013)

Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial
por: Anderson, J. R., et al.
Publicado: (2016)

Pioglitazone, a PPAR-γ Activator, Stimulates BK(Ca) but Suppresses IK(M) in Hippocampal Neurons
por: Chen, Tsang-Shan, et al.
Publicado: (2018)

Post-treatment with the PPAR-γ agonist pioglitazone inhibits inflammation and bacterial growth during Klebsiella pneumonia
por: Ramirez-Moral, Ivan, et al.
Publicado: (2021)

Fever of unknown origin and splenomegaly: A case report of blood culture negative endocarditis
por: Burzo, Maria Livia, et al.
Publicado: (2017)

Ischemia reperfusion-induced metastasis is resistant to PPARγ agonist pioglitazone in a murine model of colon cancer
por: Tashiro, Yoshihiko, et al.
Publicado: (2020)

Retraction Note: Carvacrol and PPARγ agonist, pioglitazone, affects inhaled paraquat-induced lung injury in rats
por: Amin, Fatemeh, et al.
Publicado: (2022)

The PPAR-γ Agonist Pioglitazone Modulates Proliferation and Migration in HUVEC, HAOSMC and Human Arteriovenous Fistula-Derived Cells
por: Ciavarella, Carmen, et al.
Publicado: (2023)

Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats
por: Khazaei, M., et al.
Publicado: (2012)

Angiopoietin-2 impairs collateral artery growth associated with the suppression of the infiltration of macrophages in mouse hindlimb ischaemia
por: Tan, Xiaoyong, et al.
Publicado: (2016)

Pioglitazone Reduces β Amyloid Levels via Inhibition of PPARγ Phosphorylation in a Neuronal Model of Alzheimer’s Disease
por: Quan, Qiankun, et al.
Publicado: (2019)

The PPARγ agonist pioglitazone prevents TGF-β induced renal fibrosis by repressing EGR-1 and STAT3
por: Németh, Ágnes, et al.
Publicado: (2019)

Apoptosis rate and transcriptional response of pancreatic islets exposed to the PPAR gamma agonist Pioglitazone
por: Lamounier, Rodrigo N, et al.
Publicado: (2013)

Retinal VEGF-A Overexpression Is Not Sufficient to Induce Lymphangiogenesis Regardless of VEGF-C Upregulation and Lyve1(+) Macrophage Infiltration
por: Wada, Iori, et al.
Publicado: (2021)

Pioglitazone Attenuates Drug-Eluting Stent-Induced Proinflammatory State in Patients by Blocking Ubiquitination of PPAR
por: Wang, Zhongxia, et al.
Publicado: (2016)

The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond
por: Devchand, Pallavi R., et al.
Publicado: (2018)

Changes in bone biological markers after treatment of Iranian diabetic patients with pioglitazone: No relation to polymorphism of PPAR-γ (Pro12Ala)
por: Namvaran, Fatemeh, et al.
Publicado: (2013)

Changes in bone biological markers after treatment of Iranian diabetic patients with pioglitazone: No relation to polymorphism of PPAR-γ (Pro12Ala)
por: Mottaghi, Peyman
Publicado: (2013)

Pioglitazone, a PPARγ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice
por: Kurhe, Yeshwant, et al.
Publicado: (2016)

Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study
por: Liu, Chi-Hung, et al.
Publicado: (2020)

Enhanced 3T3-L1 Differentiation into Adipocytes by Pioglitazone Pharmacological Activation of Peroxisome Proliferator Activated Receptor-Gamma (PPAR-γ)
por: Teixeira, Catarina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sgk1asjjn4tesq78k9u9jm6gvl